keratoconjunctivitis sicca

Disease ID:1203
Name:keratoconjunctivitis sicca
Associated with:0 targets
0 immuno-relevant targets
2 immuno-relevant ligands
dry eye disease | KCS | keratitis sicca
A dry eye syndrome characterised by a deficiency of aqueous tear film over the ocular surface; symptoms include inflammation of the cornea and surrounding tissues from drying, which can lead to damage of the ocular surface. and visual disturbance.
Database Links
Disease Ontology: DOID:12895


No target related data available for keratoconjunctivitis sicca


Ligand Approved Immuno References Clinical comments
lifitegrast  [  ( ]
Clinical Use: Lifitegrast is a topical integrin antagonist approved by the US FDA (July 2016) for the treatment of keratoconjunctivitis sicca (dry eye disease) [1-2].
Phase 3 trial results are published in [1].
Immuno Disease Comments: Approved drug for keratoconjunctivitis sicca.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed.
Immuno Disease Comments: Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.


Show »

1. Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio Jr FA, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP, OPUS-1 Study Group. (2014) Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology, 121 (2): 475-83. [PMID:24289915]

2. Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J et al.. (2012) Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett, 3 (3): 203-6. [PMID:24900456]